Wall Street analysts expect BioMarin Pharmaceutical Inc. (NASDAQ: BMRN – Get a rating) to post earnings per share (EPS) of $0.46 for the current quarter, according to Zacks Investment Research. Ten analysts have released earnings estimates for BioMarin Pharmaceutical, with estimates ranging from $0.07 to $0.65. BioMarin Pharmaceutical reported earnings per share of $0.53 in the same quarter last year, indicating a negative 13.2% year-over-year growth rate. The company is due to release its next results on Monday, January 1.
According to Zacks, analysts expect BioMarin Pharmaceutical to report annual earnings of $1.91 per share for the current year, with EPS estimates ranging from $1.32 to $2.10. For the next fiscal year, analysts expect the company to post earnings of $3.86 per share, with EPS estimates ranging from $2.69 to $4.52. Zacks earnings per share calculations are an average based on a survey of analysts who follow BioMarin Pharmaceutical.
BioMarin Pharmaceutical (NASDAQ: BMRN – Get a rating) last reported results on Wednesday, April 27. The biotech company reported earnings per share of $0.63 for the quarter, beating Thomson Reuters consensus estimate of $0.15 by $0.48. BioMarin Pharmaceutical achieved a net margin of 2.09% and a return on equity of 1.37%. In the same period a year earlier, the company posted earnings per share of $0.29.
BMRN has been the subject of several reports by research analysts. StockNews.com launched coverage on BioMarin Pharmaceutical in a research note on Thursday, March 31. They have placed a “holding” rating on the stock. Wedbush lowered its price target on BioMarin Pharmaceutical from $155.00 to $147.00 in a Thursday, April 28 research report. Truist Financial raised its price target on BioMarin Pharmaceutical from $125.00 to $135.00 in a Monday, January 10 research report. Morgan Stanley moved shares of BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and raised its price target for the company from $96.00 to $113.00 in a report from the Monday, April 25. Finally, Piper Sandler raised her price target on shares of BioMarin Pharmaceutical from $121.00 to $125.00 and gave the stock an “overweight” rating in a Thursday, February 24 report. Four investment analysts gave the stock a hold rating and eleven gave the company a buy rating. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $112.79.
In other news from BioMarin Pharmaceutical, CEO Jean-Jacques Bienaime sold 20,000 shares of the company in a transaction dated Thursday, April 28. The shares were sold at an average price of $83.79, for a total transaction of $1,675,800.00. Following the completion of the sale, the CEO now directly owns 334,983 shares of the company, valued at $28,068,225.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Also, director Denis Slamon sold 6,396 shares of the company in a transaction that took place on Monday, February 28. The shares were sold at an average price of $78.33, for a total transaction of $500,998.68. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 90,702 shares of the company worth $7,395,992. 1.75% of the shares are currently held by insiders of the company.
A number of institutional investors have recently increased or reduced their stake in the company. Ancora Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 466.7% in the third quarter. Ancora Advisors LLC now owns 425 shares of the biotech company worth $33,000 after acquiring 350 additional shares in the last quarter. Spire Wealth Management increased its stake in shares of BioMarin Pharmaceutical by 59.7% in the fourth quarter. Spire Wealth Management now owns 377 shares of the biotech company valued at $33,000 after purchasing an additional 141 shares during the period. Liberty Wealth Management LLC increased its position in BioMarin Pharmaceutical by 181.7% during the third quarter. Liberty Wealth Management LLC now owns 431 shares of the biotech company worth $34,000 after buying 278 more shares last quarter. CWM LLC increased its stake in BioMarin Pharmaceutical by 435.2% during the first quarter. CWM LLC now owns 487 shares of the biotech company valued at $38,000 after acquiring 396 additional shares during the period. Finally, Desjardins International Asset Management Inc. acquired a new position in BioMarin Pharmaceutical in Q4 worth approximately $53,000. 95.45% of the shares are held by hedge funds and other institutional investors.
Shares of NASDAQ BMRN opened at $83.31 on Tuesday. The stock has a market capitalization of $15.40 billion, a P/E ratio of 462.83, a PEG ratio of 1.81 and a beta of 0.49. The stock’s 50-day moving average price is $79.97 and its two-hundred-day moving average price is $83.47. The company has a quick ratio of 2.77, a current ratio of 4.21 and a leverage ratio of 0.25. BioMarin Pharmaceutical has a 52 week low of $71.59 and a 52 week high of $94.20.
BioMarin Pharmaceutical Company Profile (Get a rating)
BioMarin Pharmaceutical Inc develops and markets therapies for people with rare diseases and serious, life-threatening medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for BioMarin Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.